en · de · es · fr · pt
epitalon-notes.peptides6908.com › Blog › Epitalon Structure And Research Origin — Beginner to Advanced

Epitalon Structure And Research Origin — Beginner to Advanced

By Editorial Desk · published 2026-04-30 · last reviewed 2026-06-11 · Blog

Lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-06-11. Where a claim depends on a specific study, the study is described rather than over-claimed.

Epitalon Structure and Research Origin

Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.

Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.

Peptide Identity and Laboratory Handling

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.

Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.

Epitalon at a glance

PropertyValueNotes
Chemical classLinear tetrapeptideFour residues joined by three peptide bonds
SequenceAla-Glu-Asp-GlyCommonly abbreviated AEDG
Molecular formulaC14H22N4O9Free acid form
Monoisotopic massApproximately 390 DaMatches values reported from mass spectrometry
Net charge near neutral pHNegativeContributed by glutamate and aspartate side chains

Epitalon Peptide Background and Structure

Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.

The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.

The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.

Related pages on this site

Epitalon Background and Discovery

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Further detail

"The meaning of a Beethoven symphony," he wrote, "heard while the listener is walking around or lying in bed is very likely to differ from its effect in a concert hall where people sit as if they were in church." In essays published by the institute's Zeitschrift, Adorno dealt with the atrophy of musical culture that had become instrumental in accelerating tendencies—toward conformism, trivialization, and standardization—already present in the larger culture. Unsurprisingly, Adorno's studies found little resonance among members of the Project. At the end of 1939, when Lazarsfeld submitted a second application for funding, the musical section of the study was left out. Yet during the two years during which he worked on the Project, Adorno was prolific, publishing "The Radio Symphony," "A Social Critique of Radio Music," and "On Popular Music," texts that, along with the draft memorandum and other unpublished writings, are found in Robert Hullot-Kentor's translation, Current of Music. In light of this situation, Horkheimer soon found a permanent post for Adorno at the Institute. In addition to helping with the Zeitschrift, Adorno was expected to be the institute's liaison with Benjamin, who soon passed on to New York the study of Charles Baudelaire he hoped would serve as a model of the larger Arcades Project. In correspondence, the two men discussed the difference in their conceptions of the relationship between critique and artworks that had become manifest through Benjamin's "The Work of Art in the Age of its Technical Reproducibility".

=== MeSH D12.644.641 – peptides, cyclic === MeSH D12.644.641.040 – alamethicin MeSH D12.644.641.050 – amanitins MeSH D12.644.641.075 – bacitracin MeSH D12.644.641.142 – capreomycin sulfate MeSH D12.644.641.235 – cyclosporins MeSH D12.644.641.235.300 – cyclosporine MeSH D12.644.641.243 – cyclotides MeSH D12.644.641.252 – dactinomycin MeSH D12.644.641.270 – daptomycin MeSH D12.644.641.297 – depsipeptides MeSH D12.644.641.297.500 – valinomycin MeSH D12.644.641.325 – echinomycin MeSH D12.644.641.380 – ferrichrome MeSH D12.644.641.515 – mycobacillin MeSH D12.644.641.548 – nanotubes, peptide MeSH D12.644.641.582 – nisin MeSH D12.644.641.650 – octreotide MeSH D12.644.641.735 – phalloidine MeSH D12.644.641.780 – polymyxins MeSH D12.644.641.780.110 – colistin MeSH D12.644.641.780.750 – polymyxin b MeSH D12.644.641.802 – streptogramins MeSH D12.644.641.802.249 – mikamycin MeSH D12.644.641.802.374 – pristinamycin MeSH D12.644.641.802.500 – streptogramin group a MeSH D12.644.641.802.500.500 – streptogramin a MeSH D12.644.641.802.750 – streptogramin group b MeSH D12.644.641.802.750.500 – streptogramin b MeSH D12.644.641.802.812 – vernamycin b MeSH D12.644.641.802.875 – virginiamycin MeSH D12.644.641.802.875.500 – streptogramin a MeSH D12.644.641.825 – thiostrepton MeSH D12.644.641.875 – viomycin MeSH D12.644.641.875.250 – enviomycin

=== Other countries === Legislation has been implemented by Japan, Singapore, and Australia that offers subsidies and other incentives to encourage the development of drugs that treat orphan diseases.

Sources: en.wikipedia.org

Background from the literature

==== Remdesivir/baricitinib ==== In May 2020, the National Institute of Allergy and Infectious Diseases (NIAID) started the Adaptive COVID‑19 Treatment Trial 2 (ACTT-2) to evaluate the safety and efficacy of a treatment regimen consisting of remdesivir plus baricitinib for treating hospitalized adults who have a laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen, abnormal chest X-rays, or illness requiring mechanical ventilation. In November 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory-confirmed COVID‑19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The data supporting the EUA for baricitinib combined with remdesivir are based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The EUA was issued to Eli Lilly and Company.

The industry is predominantly composed of small and medium-sized enterprises (SMEs) and is heavily concentrated geographically, with 75% of registered AI company offices located in London, the South East, and the East of England. Investment in dedicated UK AI companies reached a record £2.9 billion in 2024, driven largely by international investors. However, the sector faces a persistent "scale-up gap" for companies seeking growth capital beyond the Series A stage, as well as a critical skills shortage, particularly in technical roles and understanding AI concepts. The National AI Strategy (2021) laid out a ten-year plan to invest in the AI ecosystem, support adoption, and establish a governance framework. In 2023, the UK hosted the inaugural global AI Safety Summit, leading to the Bletchley Declaration and the establishment of the AI Security Institute (AISI) to evaluate frontier AI models. The 2025 AI Opportunities Action Plan set strategic goals to secure computing infrastructure, drive public sector adoption, and build domestic AI capabilities, supported by a £2 billion investment in AI infrastructure and the creation of "AI Growth Zones". In contrast to the European Union's comprehensive AI Act, the UK has adopted a "pro-innovation", sector-specific regulatory approach. Rather than creating a single AI regulator, the UK relies on existing bodies (such as the Competition and Markets Authority, Information Commissioner, and Financial Conduct Authority) to apply cross-cutting principles to AI systems within their domains.

=== Development of the Doctor of Psychology degree === By the 1960s, psychotherapy had become embedded within clinical psychology, but for many, the PhD educational model did not offer the necessary training for those interested in practice rather than research. There was a growing argument that said the field of psychology in the US had developed to a degree warranting explicit training in clinical practice. The concept of a practice-oriented degree was debated in 1965 and narrowly gained approval for a pilot program at the University of Illinois starting in 1968. Several other similar programs were instituted soon after, and in 1973, at the Vail Conference on Professional Training in Psychology, the practitioner–scholar model of clinical psychology—or Vail Model—resulting in the Doctor of Psychology (PsyD) degree was recognized. Although training would continue to include research skills and a scientific understanding of psychology, the intent would be to produce highly trained professionals, similar to programs in medicine, dentistry, and law. The first program explicitly based on the PsyD model was instituted at Rutgers University. Today, about half of all American graduate students in clinical psychology are enrolled in PsyD programs.

Sources: en.wikipedia.org

Further detail

Though the agreement between the moisture-content profiles predicted by the diffusion model based on moisture-content gradients is better at lower moisture contents than at higher ones, there is no evidence to suggest that there are significantly different moisture-transport mechanisms operating at higher moisture contents for this timber. Their observations are consistent with a transport process that is driven by the total concentration of water. The diffusion model is used here based on this empirical evidence that the moisture-content gradient is a driving force for drying this type of impermeable timber. Differences in moisture content between the surface and the centre (gradient, the chemical potential difference between interface and bulk) move the bound water through the small passageways in the cell wall by diffusion. In comparison with capillary movement, diffusion is a slow process. Diffusion is the generally suggested mechanism for the drying of impermeable hardwoods. Furthermore, moisture migrates slowly due to the fact that extractives plug the small cell wall openings in the heartwood. This is why sapwood generally dries faster than heartwood under the same drying conditions.

Controversy soon arose over the size of UNTAG's military component, as the member states of the Security Council expected to cover the majority of the costs were irritated by its relatively large size. However, Angola, Zambia, and other states sympathetic to PLAN insisted that a larger force was necessary to ensure that South Africa did not interfere with independence proceedings. Against their objections UNTAG's force levels were reduced from the proposed 7,500 to three battalions of 4,650 troops. This slashed projected expenses by nearly 300 million dollars, but the Security Council did not approve the revised budget until 1 March 1989. The inevitable delay in UNTAG's full deployment ensured there were insufficient personnel prepared to monitor the movement of PLAN and the SADF or their confinement to bases on 1 April 1989, when the permanent cessation in hostilities was to take effect. Secretary-General de Cuéllar urged restraint in the interim on both sides to avoid jeopardising the de facto ceasefire maintained since August 1988 or the 1 April implementation schedule. Nevertheless, PLAN took advantage of the political uncertainty in the weeks following the UNTAG budget debate to begin moving its forces in Angola closer to the border. Since the early 1980s PLAN had consistently stated its intention to establish camps inside South West Africa during any future political transition, a notion rejected with equal consistency by the South African government.

pachynema Also pachytene stage. In meiosis, the third of five substages of prophase I, following zygonema and preceding diplonema. During pachynema, the synaptonemal complex facilitates crossing over between the synapsed homologous chromosomes, and the centrosomes begin to move apart from each other.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon chemically?

It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.

Where did epitalon research originate?

The compound came out of work on epithalamin, a peptide preparation derived from pineal tissue, conducted largely in Russian laboratories. Later studies in other countries examined it mainly in cell cultures and animal models.

Is epitalon a naturally occurring peptide?

The tetrapeptide sequence is a synthetic construct rather than a described circulating peptide. It was derived by analogy to peptide fractions obtained from tissue extracts, not isolated from blood or tissue as such.

What is epitalon made of?

Epitalon is a synthetic tetrapeptide built from four amino acids: alanine, glutamate, aspartate, and glycine. It is not extracted from a natural source but made in the laboratory by chemical synthesis. Its short length makes it relatively straightforward to produce at high purity.

Network